Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
To evaluate treatment tolerability, adherence and quality of life (QoL) over 1 year in MS (Multiple Sclerosis) participants who have been switched - due to persistent tolerability issues, particularly injection problems - from a subcutaneous injectable disease-modifying treatment (DMT) given several times a week (Rebif, Betaferon or Copaxone) to once weekly Avonex 30 μg given intra-muscularly. Avonex will be applied by the injection device Avonex Pen.
Epistemonikos ID: eb05ebd810db7de511b094e2df5bc07f2af203c2
First added on: May 11, 2024